Recombinant Human Fibroblast Growth Factor 2/FGF-2/FGFb (157aa)

Cat.No.: C046

Recombinant Human FGFb (157AA)
Description
Recombinant Human Fibroblast growth factor 2/Fibroblast Growth Factor Basic is produced by our E.coli expression system and the target gene encoding Gly132-Ser288 is expressed.
Accession #:P09038
Known as:Fibroblast Growth Factor 2; FGF-2; Basic Fibroblast Growth Factor; bFGF; Heparin-Binding Growth Factor 2; HBGF-2; FGF2; FGFB
Formulation
Lyophilized from a 0.2 μm filtered solution of 20mM TrisHCl, 150mM NaCl, pH 7.5.
Quality Control
Purity:Greater than 95% as determined by reducing SDS-PAGE.
BioActivity:Measured in a cell proliferation assay using BALB/c 3T3 cells.
Endotoxin:Less than 0.1 ng/?g (1 EU/?g) as determined by LAL test.
Reconstitution
Always centrifuge tubes before opening. Do not mix by vortex or pipetting.
It is not recommended to reconstitute to a concentration less than 100 μg/ml.
Dissolve the lyophilized protein in ddH2O.
Please aliquot the reconstituted solution to
Storage
Lyophilized protein should be stored at < -20°C, though stable at room temperature for 3 weeks.
Reconstituted protein solution can be stored at 4-7°C for 2-7 days.
Aliquots of reconstituted samples are stable at < -20°C for 3 months.
Background
FGF-basic is a members of the Fibroblast Growth Factors (FGFs) family.The family constitutes a large family of proteins involved in many aspects of development including cell proliferation, growth, and differentiation. They act on several cell types to regulate diverse physiologic functions including angiogenesis, cell growth, pattern formation, embryonic development, metabolic regulation, cell migration, neurotrophic effects, and tissue repair. FGF-basic is a non-glycosylated heparin binding growth factor that is expressed in the brain, pituitary, kidney, retina, bone, testis, adrenal gland liver, monocytes, epithelial cells and endothelial cells. FGF-basic signals through FGFR 1b, 1c, 2c, 3c and 4.
Publication
Use of Peptides That Block Metadherin-SND1 Interaction as Treatment for Cancer Kang Yibin, et al. (The Trustees of Princeton University patent:US20190336574 2019)+
The present disclosure related in general to methods of treating cancer by interfering with the interaction of metadherin with Staphylococcal nuclease domain-containing 1 (SND1) using peptides or other compounds that inhibit the binding of SND1 with metadherin and inhibit the activity of the MTDH-SND1 complex in tumor cells.
USE OF PEPTIDES THAT BLOCK METADHERIN- SND1 INTERACTION AS TREATMENT FOR CANCER Kang Yibin, et al. (THE TRUSTEES OF PRINCETON UNIVERSITY patent:US20170189481 2017)+
The present disclosure related in general to methods of treating cancer by interfering with the interaction of metadherin with Staphylococcal nuclease domain-containing 1 (SND1) using peptides or other compounds that inhibit the binding of SND1 with metadherin and inhibit the activity of the MTDH-SND1 complex in tumor cells.

Send Message